Gynecological cancer is defined as uncontrolled growth and spread of abnormal cells in the female reproductive organs such as cervix, uterus, ovaries, vagina, and vulva. Furthermore, several factors responsible for occurrence of gynecological cancer includes infection from virus known as HPV or Human Papillomavirus. Moreover, factors such as infertility, obesity, mutations, early start of menstruation or late start of menopause also could cause gynecological cancer.

Gynecological cancer can be treated with different medication, therapies, surgeries, or chemotherapy. The treatment of gynecological cancer also depends upon the type and stage of the cancer. There are different types of this cancer, which includes uterine, ovarian cancer, vaginal cancer, vulvar cancer and cervical cancer. Each gynecologic cancer is unique, with different signs and symptoms, different risk factors, and different prevention strategies.

However, high cost of drug development, threat of failure, and adverse effects of cancer drug therapy are factors expected to restrain growth of the gynecological cancer drug market. Conversely, advancement in cancer drug research and advent of personalized medicine approach are expected to provide lucrative opportunities for growth during the forecast period.

Gynecological Cancer Drugs Market Dynamics

In order to cater to increasing demand for gynecological cancer drugs, pharmaceutical and biotechnological companies are focusing on research and development to launch new gynecological cancer drugs in the market. Furthermore, some generic manufactures are also focusing on manufacturing patent off drugs in the generic form, for the treatment of this cancer. For instance, Dr Reddy’s Laboratories based in India, in May 2017, received US Food and Drug Administration approval to launch Doxorubicin Hydrochloride Liposome injection in the U.S. market. This Doxorubicin Hydrochloride Liposome is a therapeutic equivalent generic version of Doxil, which is a chemotherapy drug used in the treatment of certain cancer such as ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma.

Furthermore, in 2017, US FDA also approved Zejula (niraparib), which is targeted therapy drug for women with some types of ovarian, fallopian tube, or peritoneal cancers. It is also approved for women with relapsed cancer after chemotherapy. American Cancer Society, as of March 2018 has funded around 22 grants for cervical cancer, which accounted for around US$ 9.3 million. The funding value is offered to a single or group of research, which includes a specific type of a cancer or area of cancer.

Increasing prevalence of gynecological cancers, is expected to be a major factor for growth of the market. According to American Cancer Society, endometrium cancer, a type of cervical cancer, was estimated to be the most common cancer of the female reproductive organs. Furthermore, it was also estimated that 47,130 new cases of endometrial cancer will be diagnosed in the U.S. in 2012, and about 8,010 women will die from endometrial cancer. Moreover, according to American Cancer Society, ovarian cancer is the eighth most common cancer among women and in 2012 it was estimated that about 22,280 new cases of ovarian cancer will be diagnosed in the U.S., which is expected to support growth of the gynecological cancer drugs market size over the forecast period.

Gynecological Cancer Drugs Market - Regional Insights

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America accounted for the largest share in the gynecological cancer drugs market, followed by Europe market in 2016. This is attributed to increasing prevalence of cervical cancer in the U.S. According to Center for Disease Control and Prevention in 2014, 12,578 women in the U.S. ware diagnosed with cervical cancer and 4,115 women died from cervical cancer. Therefore, this is expected to lead to increasing demand for gynecological cancer drugs in North America.

Furthermore, Asia Pacific is estimated to grow at faster rate due to large population pool and government initiatives to create awareness regarding gynecological cancer. For instance, the Indian government published an operational framework for the country’s first national screening programmne, in 2016, where there will be mandatory screening for oral, breast, and cervical cancer in people over the age of 30 in 100 districts of India.

Gynecological Cancer Drugs Market - Competitive Analysis

Manufactures are involved in research and development, to enter the gynecological cancer drugs market. For instance, Oasmia Pharmaceutical AB, in May 2018, announced results from the completed phase III study with Apealea for treatment of ovarian cancer.

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

Primary Research (Trade Surveys and Experts Interviews)

Desk Research

Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.

Coherent Market Insights desk research is based on a principle set of research techniques:

National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.

Trade association, National and international media and trade press.

Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.

Scientific journals, and other technical magazines and whitepapers.

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

Micro-economic indicators

Macro-economic indicators

Environmental indicators

Socio-political indicators

Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

It provides first-hand information on the market dynamics, outlook, and growth parameters.

Industry experts validates the estimates which helps the company to cement the on-going research study.